Value30 Jan 2023 09:25
Recap on broker note: increase in target price from 100p to 130p….cheap
https://ukinvestormagazine.co.uk/aim-movers-polarean-imaging-gains-fda-approval/
Diagnostic imaging company Polarean Imaging (LON: POLX) has gained FDA approval for Xenoview, the Xenon129 hyperpolarised drug-device combination. This is the only product of its kind that has FDA approval. It provides enhanced visualisation of lung ventilation. Pricing still has to be secured. Revenues will take time to build up and the sales expertise will have to be put in place. Net cash is expected to be £2.9m at the end of 2023. Stifel Nicolaus has increased its target price from 100p to 130p. The share price rose 18% to 59p. Polarean Imaging joined AIM in March 2018 at 15p a share.